The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals (Nasdaq: KERX) have recently initiated a multi-center Phase I clinical program designed to explore the safety and efficacy of KRX-0401 (Perifosine) in combination with Revlimid (Lenalidomide) and Dexamethasone in Patients with relapsed or refractory multiple myeloma.
The clinical trial entitled "An Open-Label Phase I Study of the Safety of Perifosine in Combination with Lenalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma” is a program that will determine not only the safety and efficacy of the drug combination in the treatment of these patients but also the highest dose at which KRX-0401 can be safely administered to multiple myeloma patients when combined with Revlimid and dexamethasone.
Multiple Myeloma is dubbed as the incurable cancer while KRX-0401 is a novel, first-in-class, oral anticancer agent that modulates AKT and a number of other key signal transduction pathways, including the MAPK and JNK pathways.
The first to explore the Perifosine-Lenalidomide-Dexamethasobne combo in MM, the clinical program is being conducted entirely within the MMRC and is one of the first industry-sponsored clinical programs to open with the organization's assistance.
Find more details from the Keryx Biopharmaceuticals' press release.
Comment Preview